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ABSTRACT
Objectives: Asthma can be associated with substantial pro-
ductivity loss and activity impairment, particularly among
those with the most severe disease. We sought to assess the
performance characteristics of an asthma-speciﬁc adaptation
of the Work Productivity and Activity Impairment Question-
naire (WPAI:Asthma) in patients with either severe or
difﬁcult-to-treat asthma.
Methods: We analyzed 2529 subjects from The Epidemiol-
ogy and Natural History of Asthma: Outcomes and Treat-
ment Regimens (TENOR) study. The WPAI:Asthma was
administered at baseline and at 12 months. Asthma control
and quality-of-life were simultaneously assessed using the
Asthma Therapy Assessment Questionnaire and Mini-
Asthma Quality-of-Life Questionnaire, respectively.
Results: Severe versus mild-to-moderate asthma was associ-
ated with a greater percentage of impairment at work (28%
vs. 14%), at school (32% vs. 18%), and in daily activities
(41% vs. 21%). At baseline, greater asthma control problems
correlated with higher levels of impairment as measured
by the WPAI (work: r = 0.54, school: r = 0.37, activity:
r = 0.55). Over the 12-month follow-up period, improved
quality-of-life correlated with decreased levels of impairment
(work: r = -0.42, school: r = -0.36, activity: r = -0.48). In
multivariate analyses, greater than 10% overall work impair-
ment at baseline predicted emergency visits (OR 2.6 [1.6,
4.0]) and hospitalization (OR 4.9 [1.8, 13.1]) at 12 months.
Conclusions: The WPAI:Asthma correlates with other self-
reported asthma outcomes in the expected manner and pre-
dicts health-care utilization at 12 months when administered
to patients with severe or difﬁcult-to-treat asthma.
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Introduction
Asthma can be a signiﬁcant source of impairment.
Among adults in the United States, asthma is one of the
leading nonmusculoskeletal causes of work limitation
affecting the employment of millions of workers [1].
International data suggest similar ﬁgures worldwide
[2,3]. Economic assessments of asthma from various
sources indicate that decreased productivity at work
and school represent a considerable proportion of the
disease burden, speciﬁcally adding to indirect health
costs [4–7].
The negative impact of chronic conditions such as
asthma on an individual’s work and other activities
can be measured in different ways [8]. One approach
is to capture the burden of illness in terms of its
global impact on an individual’s quality-of-life.
Although activity impairment represents an important
component of quality-of-life, many other factors may
also come into play, making it difﬁcult to draw spe-
ciﬁc conclusions regarding lost productivity. Another
common approach to quantifying disease burden is to
estimate the indirect cost of illness based on informa-
tion derived from reimbursement databases and
employment records. Although this approach may
seem more intuitive from an economic standpoint,
such estimates can vary widely depending on the
underlying presumptions made [2]. Moreover, such
approaches often rely on narrowly deﬁned outcomes,
such as work or school days lost.
To accurately assess health-related work impair-
ment, it is important to take into account both time
lost from work, or absenteeism, as well as loss of
productivity while at work, increasingly referred to as
presenteeism [9]. These same principles apply when
assessing impairment in school-related activities as
well. The concept of presenteeism may be particularly
relevant in asthma patients who continue to work or
attend classes in spite of ongoing symptoms that may
impair their ability to perform effectively [6–10].
Unlike absenteeism, there is no single agreed upon
method for objectively measuring presenteeism. As a
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result, several self-reported questionnaires have been
developed to measure health-related productivity loss
while accounting for both absenteeism and presentee-
ism [11]. To the extent that such metrics yield quanti-
ﬁable measures of loss, they can also be used to
estimate indirect costs. Among the instruments avail-
able, the Work Productivity and Activity Impairment
(WPAI) has been studied the most extensively [12].
Both generic and disease-speciﬁc versions of the WPAI
have been validated for use in different populations. In
particular, an allergy-speciﬁc version (WPAI:AS) has
been developed and tested in patients with moderate-
to-severe allergic rhinitis [13]. In this study, we sought
to assess the performance characteristics of an asthma-
speciﬁc adaptation of the WPAI:AS (referred to as the
WPAI:Asthma) when used to measure productivity
loss and impairment in a US study sample with severe
or difﬁcult-to-treat asthma. A disease-speciﬁc version
of the WPAI could be a particularly useful tool in
asthma, especially among those with severe disease,
which can be associated with both considerable dis-
ability and indirect health costs.
Methods
Study Design
To assess the performance characteristics of the
WPAI:Asthma in patients with asthma, we used data
drawn from The Epidemiology and Natural History
of Asthma: Outcomes and Treatment Regimens
(TENOR) study. We examined the performance of the
WPAI:Asthma in relation to multiple other asthma-
speciﬁc outcomes applying a standard psychometric
approach [11,13–15]. Consistency of the WPAI:
Asthma scale was evaluated relative to asthma severity,
lung function, asthma control, and asthma-speciﬁc
quality-of-life at baseline. Responsiveness of the scale
was evaluated relative to change in quality-of-life over
12 months. Predictive properties of the scale were
evaluated relative to asthma-related health-care utili-
zation and work cessation reported at 12-month
follow-up. We did not assess criterion validity, because
there is no objective “gold standard” for health-related
productivity loss. Even for measures that are relevant
(for example, payroll records or school absence slips),
collecting and standardizing such documentation was
not feasible in a national study sample subsuming
thousands of worksites and hundreds of educational
facilities.
Subject Selection
The Epidemiology and Natural History of Asthma:
Outcomes and Treatment Regimens is a multicenter
prospective, observational cohort study of patients in
the United States assessed by their physician as having
either severe or “difﬁcult-to-treat” asthma, deﬁned as
difﬁculty adhering to regimen, requiring multiple
drugs, unable to avoid triggers, frequent exacerbation,
severe exacerbations, or unresponsive to therapy.
Detailed methodology and baseline population charac-
teristics for the TENOR study have been previously
described [16]. Brieﬂy, the data encompass 3 years
of study (2001–2004) with rolling enrollment from
diverse geographic areas and health-care settings. Sub-
jects underwent baseline and follow-up evaluations
that included both self-completed questionnaires
(described later in this article) and a comprehensive
data collection instrument (including information on
current medications and recent health-care utilization)
administered by local study coordinators. In addition,
lung function testing was also performed at each site
on an annual basis. No data were available beyond the
clinic site, for example, documentation of work hours,
school attendance, or other archival data related to
productivity or disability. All subjects continued to
receive their usual asthma treatment as indicated by
their main asthma provider. The study design and pro-
tocol were approved at each site by a central institu-
tional review board, and, when relevant, by the
institutional review board at each site.
Subjects were included in this analysis if they were
aged 13 years or older and completed the WPAI:
Asthma questionnaire both at baseline and 12-month
follow-up. Subjects with incomplete or missing data
that prevented calculation of the Global Initiative
for Asthma (GINA) classiﬁcation, Asthma Therapy
Assessment Questionnaire (ATAQ) control index, or
Mini-Asthma Quality-of-Life Questionnaire (AQLQ)
score were excluded.
Study Measures
WPAI:Asthma. To assess impairment in work, school,
and daily activities, we administered an asthma-
speciﬁc adaptation of the WPAI. Instrument items
from the original WPAI:AS questionnaire (http://
www.reillyassociates.net/WPAI_AS.html) were modi-
ﬁed, substituting all occurrences of allergy terms with
the word “asthma.” The WPAI:Asthma, like the
WPAI:AS, is composed of nine items representing
three domains: work impairment (four items), school
impairment (four items), and activity impairment (one
item) [13]. Subjects are asked to score the impact of
their asthma on their ability to work, attend classes,
and perform regular daily activity during the past
7 days. The work and school domains incorporate a
skip pattern that allows subjects to respond only to
relevant items depending on whether they are cur-
rently employed, taking classes, or both. In this analy-
sis, we evaluated school impairment only among those
who were not employed (either full- or part-time).
“Overall work impairment” was calculated as:
(Percent work time missed) + [(Percent work time
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attended) ¥ (Percent impairment while at work)], as
deﬁned by the original instrument. Thus, for a subject
reporting 10% time missed and working 90% time
with 10% impairment during those hours, the impair-
ment would be calculated as 0.10 + (0.90 ¥ 0.10)
= 19%. “Overall school impairment” was calculated
in a parallel manner. Activity impairment was scored
directly based on reported impairment, because there
is no “time missed” component. Logically, values for
each domain range from 0 to 100%, with higher
scores indicating greater impairment.
ATAQ. The ATAQ is a brief, self-administered ques-
tionnaire designed to assess level of asthma control
and identify possible disease management problems
[17]. The control index of the ATAQ comprises seven
items used to assess control over the past 4 weeks to
12 months. The index ranges from 0 to 4 (0 = no
control problems; 4 = four control problems), and has
demonstrated strong performance characteristics in
both cross-sectional and longitudinal population-
based studies [17,18].
Mini-AQLQ. To assess change in asthma-speciﬁc
quality-of-life, we used the Mini-AQLQ. The Mini-
AQLQ is a self-completed questionnaire composed of
15 items derived from the original 32-item Juniper
AQLQ [19]. Like the original AQLQ, the Mini-AQLQ
has four domains: symptoms, activity limitation, emo-
tional function, and environmental stimuli. Items are
scored on a 7-point Likert scale based on the past
2 weeks. AQLQ scores (both overall and by domain)
range from 1 to 7, with higher scores indicating better
quality-of-life. The Mini-AQLQ has demonstrated
good reliability, construct validity, and responsiveness,
but has less discriminative power than the original
AQLQ [19,20].
Lung function. To assess lung function, we used data
collected from ofﬁce-based spirometry performed in a
subset of subjects (93%, n = 2356) at baseline. All
spirometry measurements were performed according
to American Thoracic Society guidelines. For this
analysis, we used prebronchodilator forced expiratory
volume in one second (FEV1) percent predicted, cor-
rected for age, height, and race [21–23]; use of usual
medications was not speciﬁcally withheld.
GINA classiﬁcation. To assess disease severity, we cat-
egorized subjects according to the combined symptom-
FEV1-medication GINA classiﬁcation system deﬁned
by Liard et al. [24,25]. In brief, this algorithm
ﬁrst classiﬁes subjects into four categories (mild/
intermittent, mild/persistent, moderate/persistent, and
severe/persistent) based on frequency of symptoms
(shortness of breath, cough, chest tightness/heaviness,
wheeze, or nocturnal symptoms) and FEV1 % pre-
dicted. Current treatment step is then used to reclassify
subjects depending on the intensity of medical therapy.
For example, a patient who continues to demonstrate
symptoms and airﬂow obstruction consistent with
moderate/persistent disease despite treatment with
high-dose inhaled corticosteroids and a second con-
troller medication would be reclassiﬁed as severe/
persistent according to the Liard algorithm. Details on
this classiﬁcation method and its application in the
TENOR study have been previously described [26].
Because patients had to be assessed as either severe or
difﬁcult-to-treat by a physician to be included in
TENOR, very few subjects were classiﬁed as mild
(either intermittent or persistent) as deﬁned by GINA
criteria [27]. Consequently, we collapsed all subjects
into two categories, either mild-to-moderate (including
mild/intermittent, mild/persistent, and moderate/
persistent) or severe (severe/persistent), for our ﬁnal
analysis.
Asthma-related health-care utilization. A standard-
ized data collection instrument was used by study
coordinators at each site to assess asthma-related
health-care utilization in the past 3 months, including
acute oral corticosteroid use, unscheduled ofﬁce con-
tacts, emergency visits, and hospitalizations. Unsched-
uled ofﬁce contacts included both ofﬁce visits and
nonofﬁce physician contacts (i.e., phone calls). Emer-
gency visits included visits to an emergency room or
urgent care center. For this analysis, we dichotomized
each outcome as one or more events versus no events.
Statistical Approach
To evaluate the performance of the WPAI:Asthma, we
assessed work, school, and activity impairment as
measured by the scale relative to asthma severity, lung
function, asthma control, and asthma-speciﬁc quality-
of-life at baseline. We used the Wilcoxon rank sum test
to assess differences in mean productivity and impair-
ment by asthma severity (mild-to-moderate vs. severe).
We used Spearman rank correlations to test for asso-
ciations between the WPAI:Asthma and FEV1 percent
predicted, ATAQ control index, and AQLQ scores. For
the ATAQ, we used Tukey’s test to perform pair-wise
comparisons of impairment within levels of the control
index (e.g., 0 vs. 1 problem, 1 vs. 2 problems, 2 vs. 3
problems, etc.).
To evaluate the responsiveness of the WPAI:Asthma
over time, we used Spearman rank correlations to test
the association between change in WPAI:Asthma score
and change in AQLQ score during the 12-month study
period. We then repeated these same tests of associa-
tion for each speciﬁc domain of the AQLQ. The
AQLQ was chosen as the reference measure in this
case because it is the only instrument among those
administered for which responsiveness has been previ-
ously established.
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To evaluate performance of the WPAI:Asthma as a
predictor of future health events, we used multiple
logistic regression to assess the relationship between
WPAI-assessed impairment at baseline (independent
variable) and health-care utilization at 12-month
follow-up (dependent variable). To avoid assumptions
of linearity and achieve balanced groups for analysis,
we treated WPAI-assessed impairment as dichotomous
based on the median observed value (10% for work,
10% for school, 30% for activity). We ﬁrst examined
bivariate relationships, and then repeated the same
analyses adjusting for baseline health-care utilization
of the same type. In a parallel fashion, we used logistic
regression to examine the relationship between overall
work impairment at baseline and cessation of work at
12 months. All analyses were performed using SAS 9.1
(SAS Institute, Cary, NC, USA).
Results
Subject Characteristics
Baseline demographic and clinical characteristics of
the 2529 TENOR subjects included in this analysis are
described in Table 1. Subjects were predominantly
female (69%) and white (81%). Mean FEV1 (75%
predicted) was consistent with airway obstruction;
636 (27%) subjects had an FEV1 60% predicted.
Seventy-four percent of subjects reported at least one
of two concomitant atopic conditions: allergic rhinitis
(72%) or atopic dermatitis (14%). According to GINA
classiﬁcation, 97% of subjects had either moderate/
persistent (40%) or severe/persistent (57%) asthma.
Furthermore, 83% reported one or more control prob-
lems as assessed by the ATAQ control index.
Cross-Sectional Association between Productivity
Impairment and Measures of Asthma-Related Health
At baseline, 1397 (55%) subjects were employed and
233 (9%) were in school (and not employed, either
full- or part-time). Of those employed, 143 (11%)
were also attending classes; such subjects were not
analyzed further in terms of school impairment. As
shown in Table 2, subjects reported signiﬁcant levels of
overall work, overall school, and daily activity impair-
ment (21%, 25%, and 32%, respectively). Of note,
loss in productivity while at work or school accounted
for the majority of the impairment reported, with
“time missed” (absenteeism) contributing less than
10% to overall impairment, and less than 3% in the
case of mild-to-moderate asthmatics. Productivity loss
and impairment at work and at school was approxi-
mately twofold greater for subjects with severe versus
mild-to-moderate asthma (P < 0.01, all cases). A
Table 1 Baseline characteristics of 2529 TENOR subjects
included in analysis
Age, mean (range) (years) 47 (13–94)
Female, n (%) 1755 (69)
Race/ethnicity, n (%)
White 2060 (81)
Black 291 (12)
Hispanic 116 (5)
Asian/Paciﬁc Islander 43 (2)
Other or unknown 19 (1)
FEV1 % predicted (prebronchodilator), mean SD* 75 23
Comorbid conditions, n (%)
Allergic rhinitis 1818 (72)
Atopic dermatitis 363 (14)
GINA Classiﬁcation, n (%)
Mild, intermittent or persistent 66 (3)
Moderate, persistent 1024 (40)
Severe, persistent 1439 (57)
ATAQ control index, n (%)
No problems 419 (17)
1 problem 498 (20)
2 problems 836 (33)
3 problems 583 (23)
4 problems 193 (8)
*FEV1 available for 2356 (93%) of 2529 subjects.
ATAQ, AsthmaTherapyAssessment Questionnaire; FEV1, forced expiratory volume in
one second; GINA, Global Initiative for Asthma; TENOR, The Epidemiology and
Natural History of Asthma: Outcomes and Treatment Regimens;WPAI,Work Pro-
ductivity and Activity Impairment.
Table 2 Work, school, and activity impairment among 2529 TENOR subjects at baseline
WPAI:Asthma All subjects
GINA classiﬁcation
P-value*Mild-moderate Severe
Subjects currently employed n = 1397 n = 668 n = 729
Percent of work time missed 5 17 2 10 7 21 <0.0001
Percent loss in productivity while at work 20 25 13 19 26 28 <0.0001
Overall work impairment 21 27 14 21 28 31 <0.0001
Subjects attending classes (not employed) n = 233 n = 105 n = 128
Percent of class time missed 7 20 3 15 11 23 0.0018
Percent loss in productivity while at school 23 29 15 25 29 31 <0.0001
Overall school impairment 25 32 18 28 32 34 0.0002
Daily activity among all subjects n = 2529 n = 1090 n = 1439
Activity impairment 32 29 21 24 41 31 <0.0001
*Wilcoxon rank sum test comparing mild-moderate versus severe asthma as classiﬁed by GINA guidelines.
Values represent mean SD except where indicated otherwise.
“Overall” impairment = (percent of time missed) + [(1 - percent of time missed) ¥ (percent loss in productivity)].
GINA, Global Initiative for Asthma; TENOR, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; WPAI, Work Productivity and Activity
Impairment.
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similar magnitude of difference was also observed
for activity impairment between the two groups
(P < 0.0001).
At baseline, 2356 (93%) subjects completed lung
function testing. Impairment, as measured by the
WPAI:Asthma, correlated poorly with lung function.
Lower FEV1 (percent predicted) was weakly, but sig-
niﬁcantly, associated with greater overall work impair-
ment (r = -0.05, P = 0.05; n = 1316) and with greater
activity impairment (r = -0.11, P < 0.0001; n = 2356).
FEV1 was not associated with overall school impair-
ment (r = -0.09, P = 0.20; n = 209) for which there
were far fewer observations.
Impairment as measured by the WPAI:Asthma cor-
related well with asthma control as assessed by the
ATAQ control index (Fig. 1). At baseline, greater
number of control problems was associated with
greater work impairment (r = 0.54, P < 0.0001,
n = 1397), school impairment (r = 0.37, P < 0.0001,
n = 233), and activity impairment (r = 0.55,
P < 0.0001, n = 2529). Of note, however, school
impairment was not statistically different among sub-
jects with 0 to two control problems and between
subjects with three and four control problems (Tukey’s
test for pair-wise comparisons, P = 0.05).
Impairment as measured by the WPAI:Asthma was
negatively correlated with asthma-speciﬁc quality-of-
life (Table 3). At baseline, better quality-of-life (higher
AQLQ score) was associated with less work impair-
ment (r = -0.65, P < 0.0001, n = 1397), less school
impairment (r = -0.52, P < 0.0001, n = 233), and less
activity impairment (r = -0.69, P < 0.0001, n = 2529).
These relationships remained signiﬁcant for each of the
four AQLQ domains, with the symptom and activity
domains of the AQLQ consistently demonstrating
stronger associations with WPAI-assessed impairment
than the emotional and environmental domains.
Longitudinal Relationship between Productivity
Impairment and Asthma-Speciﬁc Quality-of-Life
Among subjects who completed the questionnaire both
at baseline and at 12-month follow-up, changes in
impairment as measured by the WPAI:Asthma corre-
lated with changes in asthma-speciﬁc quality-of-life
(Table 4). Longitudinally, improved quality-of-life
(increase in AQLQ score) was associated with
decreased impairment in work (r = -0.42, P < 0.0001,
n = 1242), school (r = -0.36, P < 0.0001, n = 184),
and daily activities (r = -0.48, P < 0.0001, n = 2529).
As with our cross-sectional ﬁndings, these longitudinal
relationships remained statistically signiﬁcant within
each of the four AQLQ domains, with the symptom
and activity domains of the AQLQ consistently dem-
onstrating the higher correlations.
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Figure 1 Relationship betweenWPAI-assessed
work, school, and activity impairment and
asthma control at baseline. Overall, greater
number of asthma control problems (as deter-
mined by the ATAQ control index) was associ-
ated with greater impairment on the
WPAI:Asthma. For work and activity impair-
ment, all pairwise comparisons were signiﬁ-
cantly different (adjusted P 0.05). For school
impairment, signiﬁcant differences were
observed comparing 0 to two problems with
three to four problems; however, no signiﬁcant
differences were found within each of these
groups (adjusted P > 0.05). ATAQ, Asthma
Therapy Assessment Questionnaire; WPAI,
Work Productivity and Activity Impairment.
Table 3 Correlation between WPAI:Asthma and AQLQ scores at baseline
AQLQ at baseline
Impairment (%) at baseline
Work
(n = 1397)
School
(n = 233)
Activity
(n = 2529)
Overall score -0.65 (-0.68, -0.62) -0.52 (-0.61, -0.42) -0.69 (-0.71, -0.67)
Symptom domain -0.63 (-0.66, -0.59) -0.51 (-0.60, -0.41) -0.66 (-0.68, -0.64)
Activity domain -0.64 (-0.67, -0.61) -0.50 (-0.59, -0.40) -0.69 (-0.71, -0.67)
Emotional domain -0.52 (-0.56, -0.48) -0.39 (-0.49, -0.28) -0.55 (-0.57, -0.52)
Environment domain -0.45 (-0.49, -0.40) -0.42 (-0.52, -0.31) -0.48 (-0.51, -0.45)
Values represent Spearman correlation coefﬁcients (95% CI); all signiﬁcant at P < 0.05.
AQLQ,Asthma Quality-of-Life Questionnaire;WPAI,Work Productivity and Activity Impairment.
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Productivity Impairment as a Predictor of Health-Care
Utilization and Work Cessation
Both overall work impairment and daily activity
impairment at baseline were signiﬁcant predictors of
acute corticosteroid use, unscheduled ofﬁce visit, emer-
gency visits, and hospitalizations reported at 12-month
follow-up (P < 0.01 in all cases, Table 5). Overall
school impairment at baseline was a signiﬁcant predic-
tor of acute corticosteroid use and unscheduled ofﬁce
visits at 12 months (P = 0.02), but was not signiﬁcantly
associated with emergency visits or hospitalizations. In
multiple regression analyses adjusted for baseline
health-care utilization, all observed relationships
remained statistically signiﬁcant; however, the strength
of association was modestly reduced in all cases.
Of 1397 subjects employed at baseline, 128 (9%)
were unemployed at 12 months. A predictive trend
was observed between WPAI-assessed work impair-
ment at baseline and work cessation at 12-month
follow-up. Subjects with >10% overall work impair-
ment at baseline were 44% more likely to report work
cessation at 12-month follow-up compared to those
with 10% impairment or less (OR 1.44 [1.00–2.07]).
Discussion
In this study, we used an asthma-speciﬁc version of the
WPAI to measure productivity loss and impairment
among 2529 subjects with either severe or difﬁcult-to-
treat asthma. Using the WPAI:Asthma, we found sub-
stantial levels of work, school, and activity impairment
in this population. The WPAI:Asthma correlated sig-
niﬁcantly with multiple other asthma-related outcomes
both at baseline and longitudinally, indicating that it
performed well in this population. Furthermore, our
results demonstrate that presenteeism, as measured by
self-reported productivity loss while at work or school,
accounts for a substantial proportion of the overall
impairment reported.
Although a number of reports have been published
on the cost of asthma, most of these studies estimate
indirect costs solely in terms absenteeism. Our ﬁndings
add to a growing body of literature, which attempts to
take both absenteeism and presenteeism into account.
Because of an increasing focus on the economic impact
of disease, self-report productivity instruments have
begun to gain attention as a potentially useful means
of gauging overall productivity loss [11]. To date,
however, the performance characteristics of such
instruments speciﬁc to asthma have not been reported.
To assess productivity loss and impairment in this
study, we utilized a previously validated, allergy-
speciﬁc version of the WPAI (the WPAI:AS), modifying
it for use in patients with asthma. Validity of the
WPAI:AS has been previously demonstrated in patients
with allergic rhinitis using data combined from two
Table 4 Correlation between change in WPAI:Asthma and change in AQLQ score over 12 months
Change in AQLQ
Change in impairment (%)
Work
(n = 1242)
School
(n = 184)
Activity
(n = 2529)
Overall score -0.42 (-0.47 to -0.38) -0.36 (-0.48 to -0.23) -0.48 (-0.51 to -0.45)
Symptom domain -0.41 (-0.45 to -0.36) -0.36 (-0.48 to -0.23) -0.48 (-0.51 to -0.45)
Activity domain -0.44 (-0.48 to -0.39) -0.27 (-0.39 to -0.12) -0.46 (-0.49 to -0.43)
Emotional domain -0.32 (-0.37 to -0.27) -0.18 (-0.32 to -0.04) -0.36 (-0.39 to -0.32)
Environment domain -0.21 (-0.26 to -0.16) -0.27 (-0.40 to -0.13) -0.26 (-0.30 to -0.22)
Values represent Spearman correlation coefﬁcients (95% CI); all signiﬁcant at P < 0.05.
AQLQ,Asthma Quality-of-Life Questionnaire;WPAI,Work Productivity and Activity Impairment.
Table 5 WPAI:Asthma as a predictor of asthma-related health-care utilization at 12-month follow-up
Health-care utilization
assessed at 12-month follow-up
Overall work
impairment
Overall school
impairment
Activity
impairment
Acute oral corticosteroid use
Unadjusted 1.70 (1.35–2.14)* 2.17 (1.21–3.87)* 1.83 (1.54–2.17)*
Adjusted for corticosteroid use at baseline 1.37 (1.07–1.74)* 1.90 (1.04–3.46)* 1.45 (1.21–1.73)*
Unscheduled ofﬁce contacts
Unadjusted 1.78 (1.40–2.25)* 2.12 (1.19–3.77)* 1.84 (1.54–2.19)*
Adjusted for ofﬁce contacts at baseline 1.47 (1.15–1.88)* 1.88 (1.02–3.44)* 1.53 (1.27–1.83)*
Emergency visits
Unadjusted 3.02 (1.93–4.74)* 1.02 (0.45–2.32) 2.40 (1.81–3.19)*
Adjusted for emergency visits at baseline 2.55 (1.61–4.04)* 0.71 (0.29–1.72) 1.89 (1.41–2.55)*
Hospitalizations
Unadjusted 5.59 (2.11–14.85)* 1.03 (0.34–3.17) 3.06 (1.93–4.85)*
Adjusted for hospitalizations at baseline 4.87 (1.81–13.06)* 0.83 (0.26–2.70) 2.34 (1.45–3.77)*
*Signiﬁcant at P < 0.05.
Odds ratios (95% CI) are reported for the likelihood of an event given impairment above the median observed value (10% for work, 10% for school, 30% for activity). Health-care
utilization refers to asthma-related events occurring 3 months before interview.
WPAI–Work Productivity and Activity Impairment.
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different antihistamine trials [13]. In that population,
the WPAI:AS was found to exhibit good measurement
properties relative to symptom scores. Presumably
some of these patients with allergic rhinitis may have
also had concomitant asthma; however, the actual pro-
portion of patients with asthma was not reported. In
fact, those with chronic or severe asthma would not
have been included, because use of corticosteroids was
a speciﬁc exclusion criterion in the original trials [13].
Very little other data exist on the performance of
the WPAI when used to measure productivity loss and
impairment in patients with asthma. Preliminary ﬁnd-
ings (abstract only) from a Swedish study of 785
employed subjects with asthma found that productiv-
ity loss at work measured by the WPAI correlated well
with disease severity and with the Short Form 36 (SF-
36), a generic measure of health status [28]. Although
such results are consistent with adequate performance
of the scale, there was not sufﬁcient detail in that brief
report to determine which version of the WPAI was
administered or the speciﬁc manner in which it was
adapted for use in asthma.
The current study adds signiﬁcantly to this area of
research by presenting detailed performance data for
an asthma-speciﬁc version of the WPAI that is both
short and easy to administer. Rather than relying on
simple symptom scores or generic health status instru-
ments as used in previous disease-speciﬁc validations
[13,28], we were able to demonstrate the consistency
of the scale against a range of well-accepted asthma-
speciﬁc measures (including GINA classiﬁcation,
ATAQ score, and the AQLQ). In addition to perform-
ing cross-sectional analyses, we also evaluated the
longitudinal performance of the WPAI:Asthma by
assessing its responsiveness to changes in asthma-
speciﬁc quality-of-life and as a predictor of health-care
utilization at 12-month follow-up. These results com-
prise the most comprehensive assessment of the WPAI
in asthma to date.
In contrast to the strong relationship between the
WPAI:Asthma and other self-reported measures, we
found very weak, albeit statistically signiﬁcant corre-
lations between work and activity impairment and
FEV1. This ﬁnding is not particularly surprising,
however, given that FEV1 is known to correlate poorly
with patient-reported symptoms and quality-of-life
[29–32], and has been shown to be a weak predictor of
work disability [33].This lack of correlation is consis-
tent with the presumption that health-related produc-
tivity impairment represents a distinct construct that
reﬂects the conﬂuence of multiple factors of which
airway obstruction is only one contributor.
Whereas previous studies have either focused solely
on work impairment, or combined work with
nonwork impairment [14,15], we used the WPAI:
Asthma to separately assess impairment at work, at
school, and in daily activities. Although the WPAI
performed well overall, differences were observed
between the individual subscales. In general, the per-
formance characteristics of the work impairment and
activity impairment scales were stronger than those
observed for school impairment. For example, we
found signiﬁcant differences in work and activity
impairment between each level of asthma control,
whereas school impairment showed poorer discrimina-
tion between those with 0 to two control problems and
between those with three or more control problems
(Fig. 1). Additionally, both the work and activity
impairment scales demonstrated good predictive valid-
ity in relation to all four health-care utilization mea-
sures assessed at 12-month follow-up, whereas there
was no signiﬁcant association between school impair-
ment and either emergency visits or hospitalization
after multivariate adjustment. Because there were
fewer subjects in school (n = 233) than working
(n = 1397) or performing any activity (all subjects,
n = 2529), this may have reduced our ability to detect
weaker associations. There may also be additional
factors that inﬂuence why persons might choose to
attend or miss class despite their asthma symptoms,
accounting for the increased variance between
measures.
Although combining results from the different sub-
scales is feasible when dealing with the comparison of
mixed populations, we feel that such an approach is
less desirable because of the heterogeneity of effects
introduced. By assessing and presenting each type of
impairment separately, we believe this provides greater
insight into the performance characteristics of each
subscale, allowing future investigators to make
informed decisions when interpreting results for these
different forms of impairment. Further studies,
however, will be needed to delineate the performance
of the WPAI:Asthma in assessing school impairment
among children and adolescents.
Our results also expand upon existing data in other
ways. Unlike prior validation studies that describe the
performance of the WPAI based on the secondary
analysis of clinical trial data, our study design repre-
sents an epidemiologic-based assessment of productiv-
ity loss and impairment among subjects that continued
to receive medication and treatments for asthma as
indicated by their treating physician. Moreover, the
sample size of the TENOR study is substantially larger
than that of typical validation studies or clinical trials
on which such studies are commonly based.
Despite these strengths, we acknowledge that our
study has important limitations. The large, multicenter
design of the TENOR study precluded the systematic
collection of ancillary data that might theoretically be
available from a smaller, more narrowly deﬁned
cohort. Speciﬁcally, it was not realistically feasible for
us to obtain payroll slips, attendance cards, or any
other externally and independently validated measure
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of absenteeism. Similarly, assessing construct validity
for nonabsentee productivity loss (presenteeism) might
involve direct observation of each subject or task-
speciﬁc quantiﬁcation (for example, key strokes per
minute in a secretarial position) and thus is even more
remote from the realities of a large multicenter cohort
study such as TENOR. The present analysis therefore
is not and does not claim to be a conﬁrmation of the
fundamental construct validity of the WPAI.
We assessed the performance characteristics of the
WPAI:Asthma within a predeﬁned population with
either physician-assessed severe or difﬁcult-to-treat
disease. This approach therefore inherently included
some patients with mild or moderate asthma who were
enrolled on the basis of being “difﬁcult-to-treat.”
Although we recategorized subjects by GINA classiﬁ-
cation to evaluate the discriminant properties of the
WPAI:Asthma, it must be noted that patients classiﬁed
as mild-to-moderate in the TENOR study are by deﬁ-
nition more severe than the typical patient with mild or
moderate asthma because they also had to be consid-
ered difﬁcult-to-treat to meet the study inclusion crite-
ria [27]. Despite this increased homogeneity within the
study population, we still found signiﬁcant differences
in productivity and impairment by GINA classiﬁca-
tion. In fact, focusing on severe or difﬁcult-to-treat
patients may have allowed us to detect more subtle
relationships, such as the association between impair-
ment and future health-care utilization; a ﬁnding that
may not have been substantiated in a more general
asthmatic population. Because we chose to study more
severe patients, however, our results may be less gen-
eralizable to those with milder disease. It is possible
that the WPAI:Asthma could demonstrate a greater
ceiling effect (more persons with 0% impairment) if
applied to those with very mild or intermittent symp-
toms. Although interesting, this hypothesis could not
be tested in the present study population.
Conclusion
TheWPAI is one of few validated instruments designed
to assess productivity loss and impairment accounting
for both absenteeism and presenteeism. In this study,
we used an asthma-speciﬁc version of the WPAI,
referred to as the WPAI:Asthma, applying it to a natu-
ralistic cohort with severe or difﬁcult-to-treat disease.
We found signiﬁcant levels of work, school, and activ-
ity impairment, with presenteeism accounting for a
substantial proportion of the disability reported.
Although we could not directly assess criterion valid-
ity, the WPAI:Asthma performed well in this study
population, correlating robustly with other asthma-
speciﬁc outcomes, both at baseline and longitudinally.
In addition to serving as a potential basis for economic
evaluations, the WPAI:Asthma provides a simple self-
reported means of measuring the impact of asthma on
productivity as a standard patient-reported outcome,
thus making it a potentially useful tool for employers,
pharmaceutical studies, and health service researchers
alike.
Source of ﬁnancial support: The TENOR study is cospon-
sored by Genentech, Inc. and Novartis Pharmaceuticals
Corp.
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